

ADVANCES IN CHRONIC HEPATITIS C: MANAGEMENT AND TREATMENT

REPORTING ON EASL 2016

COMPREHENSIVE EXPERT REVIEW AND DISCUSSION OF KEY PRESENTATIONS

AN INDEPENDENT CME ACTIVITY JOINTLY PROVIDED BY POSTGRADUATE INSTITUTE FOR MEDICINE AND VIRALEAD, INC.
THE COVERAGE IS NOT SANCTIONED BY THE CONFERENCE ORGANIZERS AND IS NOT AN OFFICIAL PART OF THE CONFERENCE PROCEEDINGS.


SIX WEEKS OF SOFOSBUVIR/LEDIPASVIR (SOF/LDV) ARE SUFFICIENT TO TREAT ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: THE HEPNET ACUTE HCV IV STUDY

K. Deterding, C. Spinner, E. Schott, T. Welzel, G. Gerken, H. Klinker, U. Spengler, J. Wiegand, J. Schulze zur Wiesch, A. Pathil, M. Cornberg, A. Umgelger, C. Zöllner, S. Zeuzem, H. von der Leyen, D. von Witzendorff, M.P. Manns, H. Wedemeyer


Abstract LBO8

Study Design

- 20 patients with acute HCV G1 with known or suspected exposure to HCV within the preceding four months with documented seroconversion and/or \uparrow ALT level >10 fold




Virological Response Acute HCV Study




Deterding K, et al. 51st EASL; Barcelona, Spain; April 13-17, 2016. Abst. LBO8.

Baseline HCV RNA and Early Virological Response




Deterding K, et al. 51st EASL; Barcelona, Spain; April 13-17, 2016. Abst. LBO8.

Baseline HCV RNA and Early Virological Response



Deterding K, et al. 51st EASL; Barcelona, Spain; April 13-17, 2016. Abst. LBO8.

ALT Kinetics Over Time



Deterding K, et al. 51st EASL; Barcelona, Spain; April 13-17, 2016. Abst. LBO8.

Adverse Events

22 Possible/probable Drug-related Adverse Events until Follow-up 12

- Gastrointestinal symptoms: **4 patients (20%)**
- Fatigue: **3 patients (15%)**
- Hair loss: **3 patients (15%)**
- Headache: **2 patients (10%)**
- Skin reaction: **2 patients (10%)**
- Abdominal pain: **2 patients (10%)**
- Psychiatric disorders: **2 patients (10%)**
- Other: sleeping disorder, mouth burn, eye disorders, spleen pain

One Serious Adverse Event (SAE) Which was Unrelated to the Study Drug

Deterding K, et al. 51st EASL; Barcelona, Spain; April 13-17, 2016. Abst. LBO8.

Martin: HCV Reinfection Incidence and Outcomes Among HIV-positive MSM in Western Europe

	Incident Infection	1 st Reinfection
Number Included	606	606
Number Reinfected (%)	N/A	149 (24.6)
Median Time (Years) to Reinfection (IQR)	N/A	1.8 (1.1-3.2)
Genotypes (%)	G1: 376(70.5) G2: 13(2.4) G3: 46(8.6) G4: 96 (18)	G1: 104(73.2) G2: 1(0.7) G3: 12(8.5) G4: 25(17.6)
Genotype Switches (%)	N/A	71/136 (52.2)
Median Age at Reinfection (IQR)	39 (34-44)	41 (37-45)
Median CD4 at Reinfection		553 (412-760)
Proportion with Suppressed HIV VL		91/111 (82.0%)
Spontaneously Cleared Proportion	111/605 (18.3%)	21/135 (15.6%)

113 Treated with 87 Achieving SVR (78%)

Martin T, et al. 51st EASL; Barcelona, Spain; April 13-17, 2016. Abst. PS006.